Email updates

Keep up to date with the latest news and content from Pediatric Rheumatology and BioMed Central.

This article is part of the supplement: 2011 Pediatric Rheumatology Symposium: Abstracts

Open Access Poster presentation

Predictors of 2 year outcomes of juvenile idiopathic arthritis in a multicenter Canadian cohort: the ReACCh out experience

Natalie J Shiff8*, Kiem G Oen7, Jaime Guzman6, Nicole A Johnson1, Adam Huber4, Shirley Tse3, Lori B Tucker2, Rae SM Yeung3, Ciaran M Duffy1 and ReACCh Out Investigators5

  • * Corresponding author: Natalie J Shiff

Author Affiliations

1 Alberta Children's Hospital, Calgary, AB, Canada

2 BC Childrens Hospital, Vancouver, BC, Canada

3 Hospital for Sick Children, Toronto, ON, Canada

4 IWK Health Centre, Halifax, NS, Canada

5 Montreal Children's Hospital, Montreal, QC, Canada

6 University of British Columbia, Vancouver, BC, Canada

7 University of Manitoba, Winnipeg, MB, Canada

8 University of Saskatchewan, Saskatoon, SK, Canada

For all author emails, please log on.

Pediatric Rheumatology 2012, 10(Suppl 1):A40  doi:10.1186/1546-0096-10-S1-A40

The electronic version of this article is the complete one and can be found online at: http://www.ped-rheum.com/content/10/S1/A40


Published:13 July 2012

© 2012 Shiff et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose

The ability to predict which children with Juvenile idiopathic Arthritis (JIA) are likely to have worse outcomes would allow a more targeted aggressive approach to initial therapy. We used data from the Research on Arthritis in Canadian Children Emphasizing Outcomes (ReACCh Out), a 16-centre prospective inception cohort of children with newly diagnosed JIA, to identify predictors of 2-year outcomes present during the first 6 months after enrollment.

Methods

Data was available on 223 to 291 children depending on the analysis. The 2-year clinical outcomes were remission, a Childhood Health Assessment questionnaire (CHAQ) score of ≥0.75, and the Juvenile Arthritis Quality of Life Questionnaire (JAQQ) score. Remission was defined according to Wallace criteria (without ESR or CRP), and combined patients on and off medication. The candidate predictors listed in Table 1 were selected for their clinical relevance and forced in a stepwise manner into regression models. They underwent natural logarithmic transformation (Ln) if not normally distributed. Logistic regression was used for prediction of remission and CHAQ outcomes, and linear regression for the JAQQ score.

Table 1. Resuts of regression models using basline and 6 month variables to predict 24 month remision, CHAQ ≥ 0.75, and JAQQ score.

Results

Table 1 shows results of the regression models. The only significant independent predictor of remission at both month 0 and 6 was the number of active joints, but R2 was low (0.06 and 0.09 at month 0 and month 6 respectively). A CHAQ score ≥0.75 was a strong independent predictor of a high 24-month CHAQ at month 0 but not at month 6 (R2 of 0.22 and 0.24 respectively). The JAQQ score at both month 0 and month 6 was the only significant independent predictor of the 24 month JAQQ score (R2 of 0.09 and 0.23 respectively). There was a non-statistically significant trend for rheumatoid factor positivity to be associated with lesser chance of remission and CHAQ score ≥0.75 at 24 months.

Conclusion

As hypothesized, most measures at 6 months were better than the baseline measures at predicting 2 year outcomes. Interestingly, CHAQ score at baseline seemed a better predictor of 2 year outcome than CHAQ score at 6 months. Although only a single variable was a significant independent predictor of the outcomes in each model, all 3 models explained a larger proportion of variation in the outcome when the additional variables were included. These results highlight the relatively limited ability to predict disease course at early stage of disease, and should act as an impetus for further research into relevant clinical and biochemical markers of outcome.

Disclosure

Natalie J. Shiff: None; Kiem G. Oen: None; Jaime Guzman: None; Nicole A. Johnson: None; Adam Huber: None; Shirley Tse: None; Lori B. Tucker: None; Rae S.M. Yeung: None; Ciaran M. Duffy for the ReACCh Out Investigators: None.